Developmental and Epileptic Encephalopathy market

View All

Epileptic Encephalopathy
Epidiolex vs Fintepla: Fight in Rare Epilepsies

Epidiolex (Jazz Pharma) and Fintepla (Zogenix - Acquired by UCB) are locking horns in the rare developmental and epileptic encephalopathies (DEE) market with Epidiolex currently leading in terms of sale. Epidiolex has clocked over USD 650 million in sales and on the other hand Fintepla is far behind at just USD 74....

Find More

Developmental and Epileptic Encephalopathy
Evaluation of the Advancing Developmental and Epileptic Encephalopathy Treatment Pipeline

Developmental and Epileptic Encephalopathy (DEE) refers to a group of severe epilepsies that are characterized both by seizures, which are often drug-resistant, as well as encephalopathy, which is a term used to describe significant developmental delay or even loss of developmental skills. In Developmental and Epil...

Find More